Stephan Christgau

Stephan Christgau joined Novo A/S in September 2007 as Investment Director of Novo Seeds.

Stephan obtained his MSc degree from the Technical University of Denmark in 1988 and his PhD degree in 1992 from the Technical University of Denmark, for a project in diabetes immunology, conducted at Hagedorn Research Institute and University of California, San Francisco.

Prior to joining Novo Seeds, Stephan was Executive Vice President and Chief Operating Officer at Osteologix where he played a leading role in the development of the company, taking the lead candidate drug through all stages from lead identification to Phase II testing for osteoporosis treatment. He also played an active role in the company’s financing including a public listing in the USA on the OTC exchange through a reverse merger with a public shell company. Previously Stephan has worked in the metabolic bone disease and arthritis areas in Nordic Bioscience and Osteometer Biotech and as a protein chemist in Novo Nordisk A/S.

Stephan is the author of more than 60 scientific publications and inventor on more than 30 patent families.

Stephan serves on the board of directors of EpiTherapeutics Aps and Inagen Aps, both Danish based biotech companies.